Lycopene

Evidence Fact Sheet

Educational reference page on lycopene — the red, open-chain, acyclic carotenoid of ripe tomatoes, watermelon, pink grapefruit, guava and papaya. Mechanism-anchored, tier-graded, hedged: no treatment claims, no sales language, no brand citations. This sub-page sits inside the Carotenoids cluster hub alongside its siblings β-carotene, lutein, zeaxanthin and astaxanthin. Not medical advice.

Last reviewed 2026-05-24 · How we assess evidence →

§1 · Quick summary (60-second read)

Lycopene (C₄₀H₅₆) is built from 11 conjugated and 2 non-conjugated C=C double bonds and has no β-ionone ring at either end of the chain. That single structural fact carries two consequences: no provitamin A activity (so no vitamin-A toxicity risk at any realistically achievable intake), and an exceptional singlet-oxygen quenching efficiency (k_q ≈ 31 × 10⁹ M⁻¹·s⁻¹, ~2× β-carotene and ~100× α-tocopherol per molar).

Three things to know before you supplement:

Food matrix is determinative. Cooked, processed tomato products (sauce, paste, ketchup, juice) generally deliver more bioavailable lycopene per gram than raw tomato. Heat → all-trans → cis isomerisation, mechanical disruption → chromoplast release, oil co-ingestion → micelle formation. The Mediterranean tomato-in-olive-oil preparation is biologically optimal, not just culinary.
Cardiovascular evidence is biomarker-level only. Pooled RCTs (PMID 28129549) show ≈ −5.66 mmHg systolic blood pressure reduction (p = 0.002) and modest LDL-C improvement at ≥ 25 mg/day. No hard-endpoint RCT exists — a causal link from lycopene supplementation to reduced heart attack, stroke or cardiovascular death has not been established.
Prostate evidence is the most over-claimed area and the most stratified by tier. Observational meta (Tier B · PMID 26287411 · PMID 28440323) shows RR ≈ 0.81–0.91 highest-vs-lowest exposure. Intervention RCTs (Tier C · n = 26 and n = 40 · biomarker-only) are not powered for clinical outcomes. FDA's 2005 verdict on the totality of the evidence was "very limited credible evidence". Treatment claims are unsupported. The SELECT trial (PMID 21990298) is NOT a lycopene trial — see §6.4.

Bottom line: a Mediterranean-style diet that includes cooked tomato in olive oil delivers the most defensible lycopene exposure. If supplementation is chosen, 10–15 mg/day with a fat-containing meal is the evidence-aligned range for general antioxidant / intermediate-biomarker effects, with 15–30 mg/day used in prostate-targeted contexts subject to the §6 disclaimers. EFSA Acceptable Daily Intake is 0.5 mg/kg body weight/day. Lycopene shows no equivalent of the β-carotene smoker safety signal.

§2 · What lycopene is — and its one defining structural quirk

Lycopene (C₄₀H₅₆) is an open-chain, acyclic carotenoid distinguished by the absence of β-ionone rings at either end of the chain, conferring no provitamin A activity (hence no vitamin A toxicity risk) and exceptional singlet-oxygen quenching efficiency (k_q ≈ 31 × 10⁹ M⁻¹·s⁻¹, roughly 2× β-carotene and 100× α-tocopherol per molar).

Lycopene (molecular formula C₄₀H₅₆) is an open-chain, acyclic carotenoid built from eleven conjugated and two non-conjugated C=C double bonds. It is the red pigment of ripe tomatoes, watermelon, pink grapefruit, guava and papaya.

What sets lycopene apart from the closely related β-carotene, α-carotene and β-cryptoxanthin is what it lacks: it has no β-ionone ring at either end of the polyene chain. That single structural fact carries two consequences worth memorising before any other claim is made about lycopene.

No provitamin A activity. Lycopene is not converted to retinol in humans. There is therefore no upper-limit-of-vitamin-A toxicity risk associated with lycopene at any realistically achievable intake — a reassurance that does not extend to high-dose β-carotene supplementation.
Exceptional singlet-oxygen quenching efficiency. The 11-conjugated-double-bond chromophore is one of nature's most efficient absorbers of singlet oxygen (¹O₂). Published rate constants put k_q at roughly 31 × 10⁹ M⁻¹·s⁻¹ — about twice β-carotene and roughly 100-fold α-tocopherol on a molar basis (mechanism review by Petyaev 2016, PMID 26881023).

These two facts — the missing ring and the unusually long conjugated π-system — are the reason lycopene is studied separately from its provitamin-A cousins in spite of sharing the same C₄₀H₅₆ molecular formula.

§2.1 · all-trans vs cis — the part most consumers get wrong

In a raw, uncooked red tomato, ≥ 90 % of lycopene exists as the all-trans isomer (also written (all-E)). In human plasma and most tissues, however, the picture inverts: 50–70 % of circulating lycopene is found as cis (Z) isomers, dominated by 5-cis, 9-cis, 13-cis and 15-cis (with 5-cis being the most thermodynamically stable).

What flips the ratio is the interaction between heat processing, mechanical disruption and lipid co-ingestion:

Step	Effect on isomers	Effect on absorption
Heat (boiling, simmering, paste, sauce)	all-trans → cis conversion (5-cis enriched)	↑↑
Mechanical disruption (puree, juice, paste)	breaks plant cell walls; releases lycopene from chromoplast protein-crystalloid bodies	↑↑
Co-ingestion with dietary fat / oil	enables micelle formation in the small intestinal lumen	↑↑↑
Eating a raw tomato slice alone	almost no isomerisation; low matrix release; minimal micelle	low baseline

A crossover pharmacokinetic study by Richelle 2012 (PMID 21902859) showed that the plasma cis : trans ratio is driven not by the form of the lycopene preparation per se but by the isomer profile of the meal itself — cis-lycopene is preferentially solubilised into bile-salt micelles and packaged into chylomicrons by the enterocyte.

This is why every serious nutrition textbook repeats the counter-intuitive line: a serving of tomato paste or tomato sauce delivers more bioavailable lycopene than the equivalent weight of raw tomato. It is also why the canonical Mediterranean preparation — tomato simmered in olive oil — is more than a flavour story. It is a bioavailability story.

§3 · Food sources — why tomato sauce beats raw tomato

Lycopene is the pigment responsible for the red colour of ripe tomatoes and a handful of other fruits. Approximate concentrations in commonly consumed foods (based on USDA food-composition tables and published surveys):

Food	Lycopene (mg per 100 g)	Notes
Tomato paste	28–75	Cooked + concentrated → highest density per gram
Sun-dried tomato	≈ 45	Concentration via dehydration
Tomato sauce / pasta sauce	15–20	Usually cooked in oil → high bioavailability
Ketchup	10–17	Cooked + sugar-acid matrix
Tomato juice (canned)	9–11	Pasteurised + processed
Watermelon	≈ 4.5	Mostly all-trans; eaten raw
Guava (pink-fleshed)	≈ 5.2	Raw; tropical seasonal availability
Raw tomato	2.5–3.0	Mostly all-trans; lower bioaccessibility
Pink grapefruit	≈ 1.4	Raw
Papaya (ripe red varieties)	1.8–3.4	Wide variety dependence

Two takeaways for the educated consumer:

Processed tomato products are not nutritionally inferior to raw tomato for lycopene. On a per-gram basis they are usually substantially superior, both because of cell-wall disruption and because of the all-trans → cis isomerisation that heat introduces (Stahl 2001, PMID 11340098; Burton-Freeman 2014, PMID 25469376).
Watermelon is a credible secondary source. Roughly 1–2 cups of diced ripe watermelon supplies the same lycopene as a medium fresh tomato, with the all-trans-dominated crystalline profile typical of raw consumption. It is a useful entry point in summer dietary patterns where appetite for cooked tomato declines.

A practical educational frame to keep in mind: the food matrix is more determinative of lycopene status than the food name on the label. A salad of raw tomato slices without oil delivers a fraction of the lycopene of an identical weight of tomato sauce cooked with olive oil. The biology is in the chromoplast and the micelle, not in the species name.

§4 · Absorption, transport and tissue distribution

Lycopene follows the classical lipid-soluble micronutrient pathway. Six steps matter:

Release from food matrix. Mechanical disruption (chewing, blending, milling, cooking) and heat are required to liberate lycopene from the chromoplast protein–crystalloid bodies in which it is stored, particularly in tomato. This is the primary reason raw, intact tomato is a relatively poor delivery vehicle compared with processed tomato.
Micelle incorporation. Bile acids and dietary fat together form mixed micelles in the small intestinal lumen. Lycopene partitions into the lipid core of these micelles. No fat → no meaningful micelle → poor absorption. This is not a marginal effect; it is a near-binary gate on bioavailability.
Enterocyte uptake. Uptake at the apical membrane of the enterocyte is mediated in part by scavenger receptors SR-B1 and CD36, with passive diffusion contributing at higher luminal concentrations.
Chylomicron packaging. Inside the enterocyte, lycopene is incorporated into nascent chylomicrons and secreted into the intestinal lymphatics, eventually reaching systemic circulation via the thoracic duct.
Lipoprotein redistribution. In plasma, lycopene partitions predominantly into LDL and VLDL (approximately 75 % of total circulating lycopene), with the remainder carried in HDL. This anatomical localisation matters mechanistically (see §5): lycopene's chain-breaking antioxidant action takes place in the lipid core of the very lipoprotein particles most susceptible to peroxidation.
Tissue accumulation. Highest concentrations are reported in testis, adrenal gland, prostate, liver and adipose tissue. Skin and adipose function as long half-life reservoirs. Plasma half-life is 12–33 days, so single-meal PK studies underestimate steady-state biology (Meinke 2010, PMID 20558286, documents skin carotenoid accumulation by Raman spectroscopy).

The fat co-ingestion requirement is non-negotiable — the single most important practical point in this fact sheet, and the reason oil-based softgel preparations consistently outperform spray-dried powders in PK studies on an empty stomach. The biology imposes the constraint; formulation cannot override it.

§5 · Four mechanistic layers of action

Lycopene operates across four mechanistic layers: (1) singlet-oxygen quenching via the 11-conjugated-double-bond π-system (molecular, high confidence); (2) chain-breaking lipid antioxidant action in LDL/VLDL cores via hydrogen-atom transfer to peroxyl radicals (cellular, high confidence); (3) NF-κB pathway modulation with inconsistent human RCT confirmation (cellular, moderate confidence); and (4) IGF-1/androgen-pathway signalling in prostate epithelium (organ-system, early mechanistic interest only).

Lycopene is studied at four mechanistic layers. Educators should hold the molecular and cellular layers as high-confidence, and treat the organ-system layer (cardiovascular, prostate, skin) as evidence-graded outcomes downstream of those mechanisms — never as guaranteed clinical effects.

§5.1 · Singlet-oxygen quenching (molecular layer · high confidence)

The 11-conjugated-double-bond π-system absorbs ¹O₂ excitation energy and dissipates it as heat — physical (non-consumptive) quenching. Lycopene is not consumed stoichiometrically: one molecule deactivates many ¹O₂ events before any covalent damage occurs. Most relevant in UV-exposed tissue (skin) and in tissues with high mitochondrial throughput (retina, testis, adrenal).

§5.2 · Chain-breaking lipid antioxidant (cellular layer · high confidence)

Within the LDL lipid core, lycopene scavenges peroxyl radicals (LOO·) by hydrogen-atom transfer, slowing the propagation phase of lipid peroxidation. Biomarker meta-analyses consistently report reductions in plasma MDA, 8-iso-prostaglandin F2α and oxidised-LDL at 10–15 mg/day over 8–12 weeks (Cheng 2017, PMID 28129549; Burton-Freeman 2014, PMID 25469376). Reproducible biomarker changes — biomarker changes nonetheless.

§5.3 · NF-κB pathway modulation (cellular layer · moderate confidence)

In vitro and ex-vivo studies show down-regulation of IκB-kinase (IKK) with downstream reduction of NF-κB nuclear translocation and the transcription of TNF-α, IL-6, COX-2 and several matrix metalloproteinases. Human RCT confirmation is partial — circulating hs-CRP and IL-6 responses are inconsistent across trials, with small effect sizes when present. A plausible cellular signal, not yet a robust clinical mechanism.

§5.4 · IGF-1 / androgen-pathway signalling in prostate epithelium (organ-system layer · early)

Mechanistic interest stems from in-vitro down-regulation of the IGF-1 / PI3K / Akt axis and modulation of androgen-receptor target genes (PSA / KLK3). A pre-surgical RCT in 26 patients (Kucuk 2001, PMID 11489752) reported trends in tumour Ki-67 and IGF-1 in the lycopene arm but did not establish disease-modifying efficacy. See §7 for the full evidence stratification.

§6 · Cardiovascular evidence — honest about the tier

RCT supported

Lycopene supplementation reduces systolic blood pressure by approximately 5.66 mmHg on average (p=0.002) and improves LDL-cholesterol at doses ≥25 mg/day, though no large RCT has yet demonstrated reduction in hard cardiovascular endpoints (myocardial infarction, stroke, cardiovascular mortality).

−5.66 mmHgSystolic blood pressure reduction
≥25 mg/dayDose threshold for LDL-C improvement
−0.22 mmol/LLDL-cholesterol reduction

Two meta-analytic data sets define the current evidence base. They tell complementary but very different stories, and both must be reported honestly.

§6.1 · Intervention-RCT meta — Tier B, intermediate biomarkers

Cheng 2017 (PMID 28129549 · 21 intervention trials) pooled effect estimates for tomato products and isolated lycopene supplementation against placebo and reported:

Systolic blood pressure: lycopene supplementation reduced SBP by ≈ −5.66 mmHg (p = 0.002); the tomato-product effect was smaller and less consistent.
LDL-cholesterol: tomato supplementation reduced LDL-C by approximately −0.22 mmol/L; the isolated-lycopene effect was smaller.
Endothelial function (FMD): tomato supplementation modestly improved flow-mediated dilation.
No improvement was demonstrated for HDL-C, triglycerides or high-sensitivity CRP across pooled trials.

A second meta (Ried 2011, PMID 21163596 · 12 trials, lipid + BP) identified a dose threshold: meaningful cholesterol-lowering effects emerged at ≥ 25 mg/day, with lower doses showing weak or null effects. SBP reductions of approximately −5.6 mmHg were observed in hypertensive subgroups.

§6.2 · Observational / epidemiological meta — Tier B, dietary exposure

Cheng 2019 (PMID 28799780 · 28 prospective and case-control publications pooled) reports that higher dietary intake or plasma concentration of lycopene / tomato is associated with:

Stroke risk −26 % (highest vs lowest exposure category)
All-cause cardiovascular mortality −37 %
CVD incidence −14 %

Observational associations of this kind are subject to substantial confounding — the Mediterranean dietary pattern, socio-economic clustering, and the broader lifestyle profile of high-tomato consumers all travel with lycopene intake. The standard NIH-ODS caveat applies: these results are hypothesis-generating, not causal. They strengthen the case for tomato-rich dietary patterns; they do not establish that a lycopene capsule reproduces the association.

§6.3 · FDA 2005 — the honest cardiovascular anchor

In November 2005, in response to the American Longevity petition (Docket 2004Q-0201), FDA evaluated a proposed Qualified Health Claim linking tomato and lycopene consumption to coronary heart disease risk. The agency concluded that the totality of evidence supported only a "very limited and preliminary" qualified claim relating to tomato sauce / tomato consumption (not isolated lycopene supplements), and explicitly rejected the broader unqualified version of the cardiovascular claim. Educators should treat this verdict as the reference statement: modest, plausible, far short of A-tier randomised-controlled-trial evidence.

§7 · Prostate evidence — the most over-claimed area, the most stratified by tier

Observational meta-analysis (Tier B); intervention RCTs small/biomarker-only (Tier C)

Observational meta-analyses report that higher dietary lycopene intake is associated with 9-19% reduction in prostate cancer risk (RR 0.81-0.91 highest vs lowest exposure), but intervention RCTs are small and biomarker-only; FDA 2005 verdict was "very limited credible evidence" for any prostate claim, and isolated lycopene supplements are excluded from permitted QHC language (which applies only to tomato/tomato sauce consumption).

RR 0.86–0.91Highest vs lowest dietary lycopene exposure
RR 0.81Circulating lycopene (highest vs lowest tertile)
n=26, 3 weeksLargest intervention RCT (Kucuk 2001, pre-surgical)

This is the area where consumer marketing has historically overstated the science. The job of the educator is to separate three layers of evidence and refuse to collapse them into a single message.

§7.1 · Observational meta-analyses — Tier B (dietary exposure)

Two systematic reviews and meta-analyses represent the current best observational evidence:

Chen 2015 (PMID 26287411 · Medicine, Baltimore · 26 studies, 17,517 prostate cancer cases, 563,299 participants) found a linear dose-response: higher dietary intake and higher circulating lycopene were both associated with reduced prostate cancer risk. The pooled relative risk for the highest vs lowest dietary-lycopene category was approximately 0.86–0.91. Heterogeneity was moderate; publication bias was present in some subgroups.
Rowles 2017 (PMID 28440323 · Prostate Cancer and Prostatic Diseases · 42 studies, 43,851 cancer cases, 692,012 participants) independently confirmed an inverse association for both dietary intake (RR ≈ 0.88) and circulating lycopene (RR ≈ 0.81, highest vs lowest tertile). A dose-response gradient was demonstrated for dietary exposure.

A complementary pooled analysis (Wang 2015, PMID 26372549) combined carotene and lycopene data and reported consistent direction.

Educator interpretation: these are observational data with stable but modest effect sizes. They support a dietary recommendation to include lycopene-rich foods in a healthy eating pattern. They do not support a treatment claim — no observational meta-analysis can. Effect estimates of this magnitude are also vulnerable to residual dietary and lifestyle confounding.

§7.2 · Intervention RCTs — Tier C (small, short, biomarker only)

Only two often-cited human intervention trials anchor this layer, and both are small and short:

Kucuk 2001 (PMID 11489752) — 26 patients scheduled for radical prostatectomy received 15 mg lycopene twice daily for 3 weeks pre-operatively. The lycopene arm showed trends in tumour Ki-67 and IGF-1. Phase II in design; not powered for clinical outcomes; exposure window of three weeks.
Schwarz 2008 BPH (PMID 18156403) — 40 patients with benign prostatic hyperplasia received 15 mg/day lycopene for 6 months. The lycopene arm showed stabilisation of IPSS symptom score and prostate volume relative to placebo. n = 40 is small; the result is hypothesis-generating, not practice-changing.

These trials do not justify any treatment claim for prostate cancer or benign prostatic hyperplasia. Cited in isolation they are often mis-presented; cited honestly they are encouraging signals that justify further trial investment, no more and no less.

§7.3 · FDA 2005 Qualified Health Claim decision — the regulatory anchor

In the same November 2005 decision discussed in §6.3 (American Longevity petition, Docket 2004Q-0201), FDA evaluated proposed claims linking tomato and lycopene intake to prostate, ovarian, gastric and pancreatic cancers. For all four cancer categories, FDA:

Rejected the petitioned unqualified health claims.
Permitted highly hedged language only for tomato consumption (not for isolated lycopene supplements) with the regulatory verdict that supporting evidence was "very limited credible evidence" — the lowest tier of the QHC framework.
Required a mandatory disclaimer accompanying any permitted use of the qualified claim.

This decision is the single most important honest data point for prostate educational copy. The regulator with full access to the evidence base said: tomato consumption (not supplements), very limited credible evidence, mandatory hedging.

§7.4 · NEVER attribute SELECT to lycopene — independent callout

SELECT is a selenium + vitamin E trial — NOT a lycopene trial

A persistent and damaging mis-citation in popular prostate content attributes the SELECT trial (Selenium and Vitamin E Cancer Prevention Trial · Klein 2011 SELECT, PMID 21990298, JAMA) to lycopene. It is not. SELECT randomised 35,533 men to one of four arms — selenium, vitamin E, both, or placebo — and reported that vitamin E 400 IU/day significantly increased prostate cancer risk (HR 1.17, p = 0.008). Lycopene is not part of the SELECT design and is not the subject of any SELECT outcome.

Editorial guardrail: any educational copy that references SELECT in support of a lycopene argument is a red-flag indicator of poor source discipline and must be rejected at review. The SELECT data say nothing — for or against — about lycopene supplementation. Cite SELECT only to disambiguate it from lycopene.

§7.5 · How to write about prostate honestly

In practice the three-layer stratification means:

Dietary tomato / lycopene patterns may be discussed in association language ("higher dietary intake has been associated with reduced prostate cancer risk in observational studies"), with the observational caveat surfaced.
Intervention RCTs may be discussed as biomarker-level signals from small, short trials.
The FDA 2005 verdict may be quoted verbatim as the regulatory baseline.
The phrases "treats prostate cancer", "prevents prostate cancer", "shrinks the prostate" must never appear — unsupported by evidence and out of compliance in every cluster region.

§8 · Skin and UV evidence — supplementary, never a sunscreen replacement

RCT supported

Three randomized controlled trials demonstrate that oral lycopene supplementation increases the minimal erythema dose (MED) by approximately the equivalent of SPF 1.3–1.5, reducing UV-induced erythema area by ~40% over 10-12 weeks at 16 mg/day; this is biologically meaningful supportive antioxidant defence but far below SPF 30+ broad-spectrum sunscreen and must be positioned as supplementary, never as a replacement.

~40%UV-induced erythema area reduction
SPF 1.3–1.5 equivalentMED (minimal erythema dose) gain
16 mg/day × 12 weeksTypical intervention dose & duration

Three randomised controlled trials form the core human evidence for the oral-photoprotection narrative around lycopene. The evidence is consistent in direction, modest in magnitude, and very specific in interpretation.

Stahl 2001 erythema (PMID 11340098 · J Nutr · 9-subject crossover, 10 weeks): 40 g/day tomato paste (≈ 16 mg lycopene) plus olive oil reduced UV-induced erythema area by approximately 40 % compared with the no-tomato control arm.
Rizwan 2011 photodamage (PMID 20854436 · Br J Dermatol · 20 subjects, 12 weeks): 55 g/day tomato paste (≈ 16 mg lycopene) reduced UV-induced erythema and MMP-1 mRNA induction, with biopsy-confirmed reduction in mitochondrial-DNA damage.
Grether-Beck 2017 UV (PMID 27662341 · Br J Dermatol · 65 subjects, 12 weeks, double-blind placebo-controlled): an oral tomato nutrient complex (with co-arms incorporating lutein) inhibited UVA1- and UVA/B-induced upregulation of HO-1, ICAM-1 and MMP-1 in human skin. This same study is a shared anchor for the Lutein / Zeaxanthin sibling pages.

§9 · Safety, lycopenodermia, and the smoker contrast with β-carotene

Lycopene has a clean cumulative safety record across more than 50 human RCTs at doses up to and including 75 mg/day for periods up to several months.

Domain	Status	Source
EFSA Acceptable Daily Intake (ADI)	0.5 mg/kg body weight/day (≈ 30 mg/day for a 60 kg adult)	EFSA 2008 re-evaluation
Long-term human tolerance	≤ 75 mg/day with no serious adverse events reported	Cumulative RCT record
Lycopenodermia (lycopene skin pigmentation)	Reversible orange-yellow skin discolouration at chronic high intake (typically > 75 mg/day for many weeks). Benign and fully reversible on discontinuation. Distinct from jaundice — no scleral (eye-white) involvement, no bilirubin elevation. Distinct from carotenodermia (β-carotene-mediated palmar / plantar yellowing).	Case reports reviewed in Petyaev 2016 (PMID 26881023)
Gastrointestinal side effects	Rare; occasional mild GI discomfort at high doses	Multiple RCT
Drug interactions	Minor potential additive effect with statins (lipid) and antihypertensives (blood pressure); not a contraindication, but worth flagging to clinician for patients on therapy	CV meta record
Pregnancy / lactation	Dietary levels safe; supplemental high doses lack pregnancy-specific data — defer to clinician	—
Paediatric supplementation	Dietary intake safe; supplemental forms not generally recommended below 18 y	—

Lycopenodermia is a cosmetic phenomenon, not a toxicity. It develops at chronically high intakes (case reports centre on intakes well above the EFSA ADI), is dose-dependent, reverses fully on return to normal intake, and is distinguished from jaundice by the absence of scleral colour change and bilirubin elevation. It is also distinct from carotenodermia, the β-carotene-mediated yellowing concentrated in palmar and plantar skin (and similarly without scleral involvement). No serious health consequence has been reported.

§9.1 · Important contrast with β-carotene

The CARET (Beta-Carotene and Retinol Efficacy Trial) and ATBC (Alpha-Tocopherol Beta-Carotene Cancer Prevention) trials demonstrated that high-dose β-carotene supplementation increases lung cancer risk in current smokers — a major historical safety lesson covered in full on the Beta-Carotene sibling page. Lycopene shows no equivalent safety signal in smokers across the cumulative evidence base. This is one of the few clean, structurally rooted differentiators within the carotenoid family, and it is one of the most educationally valuable contrasts to surface for consumers who associate "carotenoid supplement" generically with the CARET-era safety concern.

§10 · Regulatory status across US / EU / CN / BR

Region	Regulatory category	Permitted educational positioning	Notes
United States (FDA)	GRAS food ingredient + dietary supplement ingredient + five separate Qualified Health Claims (4 cancer + 1 cardiovascular, all from the November 2005 American Longevity decision)	Structure / function claims permitted with the standard FDA disclaimer; the 2005 QHCs are permitted only with mandatory hedging language and reference to "very limited / limited credible evidence"	Multiple GRAS notifications cover the supply landscape across synthetic, tomato-derived oleoresin, Blakeslea trispora fermentation and tomato-concentrate sources; no upper limit set
European Union (EFSA)	Food colorant E160d + novel-food / supplement ingredient	All Article 13.1 health-claim applications relating to lycopene's cardiovascular, antioxidant, skin-UV and vision functions were rejected in 2010–2011. Lycopene cannot bear functional health claims in EU consumer-facing materials; it can be sold as a colorant and as a supplement ingredient only.	EFSA ADI 0.5 mg/kg bw/day
China (NMPA)	Novel food ingredient (NHFPC Notice No. 12, 2008) + permitted raw material for registered health food (Blue Cap registration pathway)	A registered health-food finished product may carry "antioxidant" or "immune support" functional claims if the finished product itself is registered. Loose ingredient copy without finished-product registration cannot make functional claims.	Synthetic-biology / fermentation sources require additional process and safety data submission
Brazil (ANVISA)	Dietary supplement raw material under RDC 243/2018 + functional food ingredient	Antioxidant-class educational language is permitted; therapeutic / disease-modifying claims are not	Oleoresin-based softgel is the dominant local market format

For evidence-dense educational pages like this fact sheet, the safest cross-region position is: describe mechanism and food-source biology; describe evidence tiers honestly; do not bind any disease claim to product action. That position is compliant in every region covered above without requiring region-specific edits.

§11 · How an educated consumer evaluates a lycopene supplement

10–15 mg/day is evidence-aligned for general antioxidant and cardiovascular intermediate-marker effects; 15–30 mg/day is used in prostate-targeted contexts subject to observational and biomarker-only evidence limitations; EFSA Acceptable Daily Intake is 0.5 mg/kg body weight/day (≈30 mg/day for a 60 kg adult); cumulative human tolerance documented to ≤75 mg/day with no serious adverse events, though chronic high intake (>75 mg/day for many weeks) can produce reversible benign lycopenodermia (orange-yellow skin discolouration without scleral involvement or bilirubin elevation).

If a reader has already decided to use a lycopene supplement, the dimensions below are the ones the published evidence speaks to most clearly. This is self-assessment guidance, not purchase steering.

Dimension	What to look for	Why it matters
Daily dose	10–15 mg/day is the typical evidence-aligned range for general antioxidant and cardiovascular intermediate-marker support; 15–30 mg/day for prostate-targeted use (subject to the §7 tier disclaimers)	Below 10 mg/day the intervention-RCT signal weakens; above 30 mg/day the marginal benefit flattens
Form	Oil-based softgel > microencapsulated water-dispersible powder > crystalline raw material (the last requires fat-containing co-meal)	Reflects the §4 absorption biology
Isomer profile	Oleoresin from heat-processed tomato and oleoresin from Blakeslea trispora fermentation both tend to carry a higher cis-isomer fraction, which is pharmacokinetically favourable	Cis-isomers are preferentially incorporated into chylomicron lipid (Richelle 2012, PMID 21902859)
Co-meal practice	Take with a fat-containing meal — for example with breakfast or lunch that includes any oil, dairy fat, nut or avocado. Not with water on an empty stomach.	Without fat, micelle formation is poor and absorption is low regardless of formulation quality
Source transparency	Tomato extract / tomato oleoresin / fermentation-derived / synthetic — each source is legitimate, but the label should disclose which. Consumers with tomato allergy or fermentation sensitivities particularly need this clarity.	Consumer-rights baseline
Companion antioxidant profile	Tomato oleoresin naturally carries trace tocopherols, phytosterols and other lipophilic micronutrients — read the full panel rather than the headline figure. This is contextual information, not a "free upgrade".	Avoids double-counting these as headline actives

The single most under-appreciated practical point is fat co-ingestion. Most suboptimal lycopene regimens fail not on dose and not on formulation but because the capsule was taken with water on an empty stomach. The biology imposes the rule; no marketing claim overrides it.

Cluster sibling pages

This sub-page sits inside the Carotenoids cluster hub. Each sibling extends the educational frame in a complementary direction.

Carotenoids hub — Parent hub · Lycopene is the prototype open-chain, non-provitamin-A carotenoid — the structural counter-example to the β-ionone-ring family
Beta-Carotene — Same C₄₀H₅₆ formula but cyclised · provitamin A · CARET / ATBC smoker risk signal makes this the direct structural and safety contrast to lycopene
Lutein — Oxygenated xanthophyll · macular tissue specificity vs lycopene's testis / adrenal / prostate distribution · shared skin-photoprotection evidence via Grether-Beck 2017 UV (PMID 27662341)
Zeaxanthin — Macular pair-partner with lutein · oxygenated xanthophyll concentrated in the macula rather than in the systemic lipid compartments where lycopene accumulates
Astaxanthin — Oxygenated keto-carotenoid · the comparator most often invoked for "stronger antioxidant" marketing · structural contrast teaches structure → quenching efficiency as a continuum

§13 · References

All 16 lycopene-relevant PMIDs verified against PubMed (2026-05-24). PMID 21990298 (SELECT) is cited only for the §7.4 disambiguation callout; SELECT is not a lycopene trial.

Lycopene-specific PMIDs cited on this page

PMID 26881023 · Petyaev IM 2016 · "Lycopene metabolism and its biological significance" · Oxidative Medicine and Cellular Longevity · mechanism review · singlet-oxygen quenching k_q ≈ 31 × 10⁹ M⁻¹·s⁻¹
PMID 21902859 · Richelle M et al. 2012 · "Lycopene cis-trans isomer pharmacokinetics" · crossover PK · cis-lycopene preferentially solubilised into bile-salt micelles
PMID 11340098 · Stahl W et al. 2001 · "Carotenoids and carotenoids plus vitamin E protect against UV-induced erythema in humans" · J Nutr · 9-subject crossover, 10 weeks · 40 g/day tomato paste + olive oil → ~40 % erythema reduction · MED gain ~SPF 1.3–1.5 equivalent
PMID 25469376 · Burton-Freeman B, Sesso HD 2014 · "Whole food versus supplement: tomato intake and lycopene supplementation on cardiovascular risk factors" · Adv Nutr
PMID 20558286 · Meinke MC et al. 2010 · "Carotenoid pigments in the skin assessed by Raman spectroscopy" · Eur J Pharm Biopharm · skin reservoir accumulation
PMID 28129549 · Cheng HM et al. 2017 · "Lycopene and risk of cardiovascular diseases" · 21 intervention trials · SBP −5.66 mmHg (p = 0.002) · LDL-C improvement at ≥ 25 mg/day · biomarker-only · no hard-endpoint trial
PMID 21163596 · Ried K, Fakler P 2011 · "Tomato and lycopene supplementation and cardiovascular risk factors" · Maturitas · 12 trials · cholesterol-lowering threshold ≥ 25 mg/day · SBP ≈ −5.6 mmHg in hypertensive subgroups
PMID 28799780 · Cheng HM et al. 2019 · "Tomato / lycopene intake and cardiovascular events: dose-response meta-analysis of observational studies" · Eur J Nutr · stroke −26 % · CV mortality −37 % · CVD incidence −14 % · observational, hypothesis-generating only
PMID 26287411 · Chen P et al. 2015 · "Dietary lycopene, tomato products and prostate cancer risk: systematic review and meta-analysis" · Medicine (Baltimore) · 26 studies, 17,517 prostate cancer cases, 563,299 participants · RR ≈ 0.86–0.91 highest vs lowest dietary category · linear dose-response
PMID 28440323 · Rowles JL 3rd et al. 2017 · "Increased dietary and circulating lycopene are associated with reduced prostate cancer risk" · Prostate Cancer Prostatic Dis · 42 studies, 43,851 cancer cases, 692,012 participants · dietary RR ≈ 0.88 · circulating RR ≈ 0.81 highest vs lowest tertile
PMID 11489752 · Kucuk O et al. 2001 · pre-surgical prostatectomy RCT · n = 26 · 15 mg lycopene bid × 3 weeks · trends in tumour Ki-67 and IGF-1 · phase II · not powered for clinical outcomes
PMID 18156403 · Schwarz S et al. 2008 · "Lycopene inhibits disease progression in patients with benign prostate hyperplasia" · J Nutr · n = 40 · 15 mg/day × 6 months · IPSS / prostate-volume stabilisation · hypothesis-generating, not practice-changing
PMID 26372549 · Wang Y et al. 2015 · pooled carotene + lycopene analysis · consistent inverse direction
PMID 20854436 · Rizwan M et al. 2011 · "Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo" · Br J Dermatol · 20 subjects, 12 weeks · 55 g/day tomato paste · reduced UV-induced erythema, MMP-1 mRNA induction and mitochondrial DNA damage
PMID 27662341 · Grether-Beck S et al. 2017 · "Molecular evidence that oral supplementation with lycopene or lutein protects human skin against ultraviolet radiation" · Br J Dermatol · 65 subjects, 12 weeks, double-blind RCT · inhibition of UVA1- and UVA/B-induced HO-1, ICAM-1, MMP-1 upregulation
PMID 21990298 · Klein EA et al. (SELECT) 2011 · JAMA · cited ONLY to disambiguate from lycopene · SELECT randomised 35,533 men to selenium / vitamin E / both / placebo · vitamin E 400 IU/d HR 1.17, p = 0.008 for prostate cancer · lycopene was NOT in this trial — see §7.4

Regulatory and Public-Health References (not counted in PMID total)

FDA 2005 · American Longevity petition · Docket 2004Q-0201 · Qualified Health Claims for tomato / lycopene and CHD + prostate, ovarian, gastric and pancreatic cancers · all unqualified claims rejected · only highly hedged language permitted for tomato consumption · evidentiary verdict "very limited credible evidence" (lowest QHC tier)
EFSA 2008 · re-evaluation · Acceptable Daily Intake 0.5 mg/kg body weight/day (≈ 30 mg/day for a 60 kg adult)
EFSA 2010–2011 · Article 13.1 health claim applications relating to lycopene's cardiovascular, antioxidant, skin-UV and vision functions all rejected
EU food colorant code · E160d (lycopene)
China NMPA · NHFPC Notice No. 12, 2008 · novel food ingredient · permitted raw material for registered health food (Blue Cap registration pathway)
Brazil ANVISA · RDC 243/2018 · dietary supplement raw material + functional food ingredient · therapeutic / disease-modifying claims not permitted
NIH Office of Dietary Supplements · lycopene fact sheet · educational reference framing

Educational disclaimer

This page is educational content and not medical advice. It does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider for individual recommendations, especially if you are pregnant, breastfeeding, on prescription medication (particularly statins or antihypertensives), or managing a chronic condition. Brand and product names are not endorsed; the criteria described are evidence-based generic standards (oil-based softgel format, source-disclosed labelling, fat-containing co-meal practice, dose alignment with EFSA ADI) that any compliant product can meet. The phrases "treats prostate cancer", "prevents prostate cancer", "shrinks the prostate", and "oral sunscreen" are not used because they are unsupported by the current evidence base. The SELECT trial is a selenium + vitamin E study and is never attributable to lycopene.

§12 · Frequently Asked Questions

The questions below reflect the most-searched questions on lycopene across general web search and AI assistants. Answers are intentionally concise; deeper detail lives in the relevant sections above.

1. Is lycopene the same as vitamin A?

No. Lycopene is a carotenoid like β-carotene, but it lacks the β-ionone ring required for conversion to retinol. There is therefore no provitamin A activity, and no risk of vitamin A toxicity from lycopene intake — a meaningful safety difference from β-carotene at supplement-level doses.

2. Is raw tomato better than tomato sauce for lycopene?

The intuitive answer is wrong here. Cooked, processed tomato products (sauce, paste, ketchup, juice) generally deliver more bioavailable lycopene per gram than raw tomato. Heat converts a portion of the all-trans isomer to cis isomers, which are preferentially absorbed; mechanical disruption breaks the chromoplast structure that traps lycopene in raw tissue; and the typical cooking medium (oil) supplies the fat required for micelle formation. The Mediterranean preparation of tomato simmered in olive oil is, in lycopene terms, biologically optimal.

3. Does lycopene treat prostate cancer?

No. The honest answer is that observational studies link higher dietary lycopene intake to a modest reduction in prostate cancer risk (Tier B evidence) and two small intervention RCTs report biomarker-level signals (Tier C evidence). FDA's 2005 regulatory verdict on the totality of the evidence was "very limited credible evidence", the lowest tier of the Qualified Health Claim framework. There is no evidence that lycopene treats, prevents or cures prostate cancer at the level required for a treatment claim.

4. I read that the SELECT trial showed lycopene increases prostate cancer risk — is that right?

This is one of the most common factual errors in popular prostate content. SELECT did not study lycopene. SELECT randomised men to selenium, vitamin E, both or placebo, and the headline finding was that high-dose vitamin E (400 IU/day) significantly increased prostate cancer risk. Lycopene was not in the trial. Any source that uses SELECT in a lycopene argument is mis-citing the data.

5. Does lycopene lower blood pressure?

Pooled RCT data (Cheng 2017 CV, PMID 28129549) show lycopene supplementation reduces systolic blood pressure by approximately 5.66 mmHg on average (p = 0.002) — a reproducible biomarker effect. No RCT has shown this translates into reduced stroke, heart attack or cardiovascular mortality, so the causal link to hard outcomes has not been established.

6. Can lycopene replace sunscreen?

No. Oral lycopene supplementation has been shown to increase the minimal erythemal dose (MED) — the UV dose required to produce visible reddening — by roughly the equivalent of an SPF 1.3–1.5 sunscreen. This is biologically meaningful as supportive antioxidant defence, but it is far below the SPF 30+ broad-spectrum protection recommended for sun-exposed skin. Position lycopene as supplementary to topical sunscreen, never as a replacement.

7. I noticed my skin turning slightly orange after taking lycopene — should I be worried?

This is lycopenodermia, a benign, fully reversible orange-yellow skin discolouration described in the case-report literature at chronically high intakes (typically above 75 mg/day for many weeks). It is distinct from jaundice — no eye-white (scleral) colour change, no elevation of bilirubin. Reducing intake reverses the colouration. There is no known toxicity associated with the phenomenon. Practically, it is a signal to revisit dose rather than a signal of harm.

8. Should I take lycopene with food or on an empty stomach?

With food, and specifically with food that contains fat. Lycopene is fat-soluble; without dietary fat there is insufficient micelle formation in the small intestinal lumen and absorption falls dramatically. Any meal containing oil, dairy fat, nut or avocado will support absorption. Taking lycopene with water on an empty stomach is the single most common practical mistake in lycopene supplementation.

9. How does lycopene compare to astaxanthin as an antioxidant?

Both are efficient carotenoid antioxidants with different structural and tissue-distribution profiles. Lycopene is open-chain and partitions into LDL and adipose reservoirs; astaxanthin is an oxygenated keto-carotenoid that integrates into cell and mitochondrial membranes. Citing one as "stronger" in a single number is misleading — different mechanisms operate in different compartments. See the astaxanthin sibling page for the breakdown.

10. Is synthetic or tomato-derived lycopene better?

Both are well-characterised and clinically studied. Synthetic lycopene has long been used in formal RCTs and food-fortification programmes. Tomato oleoresin and Blakeslea trispora fermentation lycopene naturally carry a higher cis-isomer fraction and trace tocopherols and phytosterols — contextual, not a free upgrade. Labels should disclose the source so consumers with tomato or fermentation sensitivities can choose informedly.

11. How long until lycopene supplementation produces measurable biomarker changes?

Intervention-RCT data typically show measurable changes in oxidative-stress markers (MDA, oxidised-LDL) and cardiovascular biomarkers (SBP, LDL-C) over an 8- to 12-week window at 10–15 mg/day or above. Plasma half-life is 12–33 days, so tissue saturation lags first dose meaningfully — the biomarker meta-analyses capture steady-state biology.

12. Is lycopene safe in pregnancy?

Dietary intake of lycopene-rich foods (tomato, watermelon, pink grapefruit) is considered safe in pregnancy. Supplemental high-dose lycopene has not been specifically studied in pregnancy, so the prudent position is to defer the supplementation decision to a clinician familiar with the individual case.

← Back to Carotenoids cluster hub · All Ingredients